Academic literature on the topic 'Antiresorptive Therapy'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antiresorptive Therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antiresorptive Therapy"

1

Pande, Ira, and David J. Hosking. "Oral antiresorptive therapy." Current Osteoporosis Reports 2, no. 4 (2004): 116–22. http://dx.doi.org/10.1007/s11914-996-0010-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pande, Ira, and David J. Hosking. "Oral antiresorptive therapy." Current Osteoporosis Reports 2, no. 4 (2004): 116–22. http://dx.doi.org/10.1007/bf02686924.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pande, Ira, and David J. Hosking. "Oral antiresorptive therapy." Current Rheumatology Reports 7, no. 1 (2005): 71–77. http://dx.doi.org/10.1007/s11926-005-0012-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dziewulska, Aleksandra, Weronika Kiełt, Julia Kozłowska, et al. "Implications in dental treatment during the use of antiresorptive drugs - a literature review." Journal of Education, Health and Sport 69 (October 3, 2024): 55356. http://dx.doi.org/10.12775/jehs.2024.69.55356.

Full text
Abstract:
Introduction: Antiresorptive drugs such as bisphosphonates and denosumab are crucial for treating osteoporosis, metastatic bone disease, and hypercalcemia by inhibiting osteoclast function. They can lead to medication-related osteonecrosis of the jaw (MRONJ) following invasive dental procedures, requiring careful management to mitigate potential adverse effects. Purpose of work: Synthesis of knowledge about the impact of taking antiresorptive drugs on aspects of dental treatment. Materials and methods: Materials used in this study were found in the PubMed and Google Scholar database, using the
APA, Harvard, Vancouver, ISO, and other styles
5

McClung, M. R. "28. Combination Antiresorptive Therapy." Menopause 5, no. 4 (1998): 244. http://dx.doi.org/10.1097/00042192-199805040-00037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bruckmoser, Emanuel, Miriam Palaoro, Lukas Latzko, Dagmar Schnabl, Sabrina B. Neururer, and Johannes Laimer. "Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know." International Journal of Environmental Research and Public Health 18, no. 9 (2021): 4466. http://dx.doi.org/10.3390/ijerph18094466.

Full text
Abstract:
Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of antiresorptive drugs. In this online survey, the awareness and knowledge of dentists regarding MRONJ was evaluated, and potential implications for oncologists are discussed. Questionnaires were emailed to dentists from Germany, Austria, Switzerland, and South Tyrol to evaluate disease-related knowledge and management. In addition to the overall score, a separate score was calculated for knowledge (maximum score: 15 points) and management (maximum score: 6 points) questions, and 1197 valid replies with completed questionnai
APA, Harvard, Vancouver, ISO, and other styles
7

BOSCHERT, SHERRY. "Encouragement Aids Antiresorptive Therapy Adherence." Family Practice News 41, no. 16 (2011): 36. http://dx.doi.org/10.1016/s0300-7073(11)70861-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Boskovic, Ksenija. "Indications for initiation of drug therapy and modern therapy protocols in patients with osteoporosis." Medical review 75, Suppl. 2 (2022): 7–12. http://dx.doi.org/10.2298/mpns22s2007b.

Full text
Abstract:
Introduction. Pharmacotherapy and physical therapy in patients with osteoporosis are aimed at increasing bone density and reducing the risk of fall in order to prevent fractures. Medications approved for the treatment of osteoporosis reduce the risk of fracture, either by reducing bone resorption or by stimulating bone formation. Bisphosphonates are most widely used antiresorptive agents that lower bone turnover markers to premenopausal levels and reduce fracture rates. Bisphosphonates bind to bone minerals and have a long-lasting effect. Long-term, continuous use of oral bisphosphonates is us
APA, Harvard, Vancouver, ISO, and other styles
9

Pimolbutr, Kununya, Stephen Porter, and Stefano Fedele. "Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature." BioMed Research International 2018 (2018): 1–14. http://dx.doi.org/10.1155/2018/8071579.

Full text
Abstract:
Objectives. To review the available literature on medication-related osteonecrosis of the jaw (MRONJ) associated with antiangiogenics in antiresorptive-naïve individuals. Methods. A literature search was performed using MEDLINE via PubMed, EMBASE, and Web of Science in December 2017. Results. We identified reports describing a total of 35 antiresorptive drugs-naïve patients who developed antiangiogenic-related MRONJ. The mean age of these patients was 59.06 years and the F : M ratio was 4 : 5. The most common underlying disease was metastatic renal cell cancer. Pain to the mandible was the mos
APA, Harvard, Vancouver, ISO, and other styles
10

Rizzoli, René. "Combined and sequential therapies with anabolic and antiresorptive drugs in the management of patients with postmenopausal osteoporosis." International Journal of Bone Fragility 3, no. 1 (2023): 7–15. http://dx.doi.org/10.57582/ijbf.230301.007.

Full text
Abstract:
The aim of osteoporosis therapy is to reduce the increased fracture risk associated with osteoporosis-related bone fragility. Prevention of fragility fracture relies on balanced nutrition, weight-bearing and balance-improving physical exercises, and pharmacological therapies. Among the latter, the antiresorptive drugs are the most widely used. Bone formation stimulators (anabolics) are second line-therapy with reversible effects once discontinued. For patients at very high risk or imminent risk of fracture, the question arises of whether combining drugs with different modes of action, or using
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antiresorptive Therapy"

1

Morin, Suzanne Nicole. "Effectiveness of antiresorptive agents for the prevention of recurrent hip factures." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=101871.

Full text
Abstract:
Osteoporosis is a common condition characterized by bone fragility and fractures. Hip fracture, leads to disability, morbidity, excess mortality and growing costs to health care systems.<br>Antiresorptive agents are used to treat osteoporosis and fractures; it is unknown if these agents are effective in preventing recurrent fractures in individuals who have sustained a hip fracture.<br>Using health services administrative databases, we ascertained the incidence of hip fractures and associated-mortality rates in the elderly population in Quebec, from 1996 to 2002 and, evaluated the effectivenes
APA, Harvard, Vancouver, ISO, and other styles
2

Würfel, Lisa [Verfasser]. "Knochenmetastasen bei Mammakarzinom : Patientenzufriedenheit und Kostenanalyse der antiresorptiven Therapie / Lisa Würfel." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2020. http://d-nb.info/123179206X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wick, Alexander [Verfasser], and Christoph [Akademischer Betreuer] Pautke. "Der Einfluss verschiedener Strategien der antiresorptiven Therapie auf den Zeitpunkt des Auftretens und den chirurgischen Therapieerfolg der Medikamenten-assoziierten Kiefernekrose / Alexander Wick ; Betreuer: Christoph Pautke." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2021. http://d-nb.info/1227188420/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hahnefeld, Lilian [Verfasser], Bettina [Akademischer Betreuer] [Gutachter] Hohlweg-Majert, and Klaus-Dietrich [Gutachter] Wolff. "Szintigraphische Untersuchung des Einflusses einer antiresorptiven Therapie mit Bisphosphonaten auf den Kieferknochenstoffwechsel bei Patientinnen mit ossär metastasiertem Mammakarzinom / Lilian Hahnefeld ; Gutachter: Bettina Hohlweg-Majert, Klaus-Dietrich Wolff ; Betreuer: Bettina Hohlweg-Majert." München : Universitätsbibliothek der TU München, 2017. http://d-nb.info/1147565546/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antiresorptive Therapy"

1

Silverman, Stuart, and Bo Abrahamsen. Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy. Springer London, Limited, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Silverman, Stuart, and Bo Abrahamsen. The Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy. Springer, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Elder, Grahame J. Metabolic bone disease after renal transplantation. Edited by Jeremy R. Chapman. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0288.

Full text
Abstract:
Patients who undergo kidney transplantation have laboratory, bone, and soft tissue abnormalities that characterize chronic kidney disease mineral and bone disorder (CKD-MBD). After successful transplantation, abnormal values of parathyroid hormone, fibroblast growth factor 23, calcium, phosphate, vitamin D sterols, and sex hormones generally improve, but abnormalities often persist. Cardiovascular risk remains high and is influenced by prevalent vascular calcification, and fracture risk increases due to a combination of abnormal bone ‘quality’, compounded by immunosuppressive drugs and reducti
APA, Harvard, Vancouver, ISO, and other styles
4

Hutchison, Alastair J., and Michael L. Picton. Fractures in patients with chronic kidney disease. Edited by David J. Goldsmith. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0121.

Full text
Abstract:
Patients with any degree of chronic kidney disease (CKD) have a much higher risk of fractures than the general population, and the risk of death at 1 year post hip fracture in a dialysis patient is over 60%, compared to less than 20% for a non-CKD patient. The assessment of fracture risk and diagnosis of the underlying skeletal pathology in CKD patients is a significant clinical challenge. Non-invasive imaging techniques are not totally reliable in the general population, and the presence of advanced CKD (stages 4, 5, and 5D) renders them largely useless. Bone strength is not determined only b
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antiresorptive Therapy"

1

Murthi, Swetha, and Emilia Pauline Liao. "Antiresorptive Therapy for Osteoporosis." In Osteoporosis. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-83951-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jain, Sumeet, and Pauline Camacho. "Adverse Effects of Antiresorptive Therapy." In Osteoporosis. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-83951-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kupperman, Eli, and Susan V. Bukata. "Fractures and Healing on Antiresorptive Therapy." In The Duration and Safety of Osteoporosis Treatment. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23639-1_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Vestergaard, Peter. "Antiresorptive Therapy, Mortality and Cancer Incidence." In The Duration and Safety of Osteoporosis Treatment. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23639-1_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bilezikian, John P., and Natalie E. Cusano. "Combination Anabolic and Antiresorptive Therapy for Osteoporosis." In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118453926.ch53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tsai, Joy N., and Mary L. Bouxsein. "Effects of Antiresorptive Therapy on Bone Microarchitecture." In The Duration and Safety of Osteoporosis Treatment. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23639-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Khan, Aliya. "Osteonecrosis of the Jaw (ONJ) and Antiresorptive Therapy." In 2015 Meet-The-Professor: Endocrine Case Management. The Endocrine Society, 2015. http://dx.doi.org/10.1210/mtp4.9781936704941.ch9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nieves, Jeri W., Lorraine Komar, Felicia Cosman, and Robert Lindsay. "Interactions Between Calcium Intake and Antiresorptive Therapy in Osteoporosis." In Nutritional Aspects of Osteoporosis. Springer New York, 1998. http://dx.doi.org/10.1007/978-1-4612-2228-6_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Leder, Benjamin Z. "Combination and Sequential Osteoanabolic/Antiresorptive Therapy in Osteoporosis Treatment." In Osteoporosis. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-69287-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ramchand, Sabashini K., and Ego Seeman. "Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy." In Bone Regulators and Osteoporosis Therapy. Springer International Publishing, 2020. http://dx.doi.org/10.1007/164_2020_354.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antiresorptive Therapy"

1

Trittler, R., A. Ermer, P. Poxleitner, and MJ Hug. "4CPS-047 Evaluation of antiresorptive agent-related osteonecrosis therapy by measuring concentrations of penicillin g in jawbone." In 28th EAHP Congress, Bordeaux, France, 20-21-22 March 2024. British Medical Journal Publishing Group, 2024. http://dx.doi.org/10.1136/ejhpharm-2024-eahp.151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wasnich, RD, MC Hochberg, S. Greenspan, PD Ross, and PD Miller. "OP0113 Increases in bone mineral density explain the reduction in incidence of nonvertebral fractures seen with antiresorptive therapy in women with postmenopausal osteoporosis." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.634.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Behanova, M., B. Reichardt, Tanja A. Stamm, J. Zwerina, K. Klaushofer, and R. Kocijan. "Mortalität und Refrakturrisiko nach Hüftfraktur in Österreich unter antiresorptiver Therapie." In Osteologie 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3402866.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mantinger, E., Radu-Lucian Jilavu, and S. Domayer. "Bilaterale atypische Femurfraktur nach langjähriger antiresorptiver Therapie. Operatives und medikamentöses Management." In Osteologie 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3402881.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antiresorptive Therapy"

1

Sacco, Roberto. A systematic review of metastatic osteonecrosis of the jaws (MOJ) in patients undergoing antiresorptive and/or antiangiogenic therapy for skeletal-related adverse events. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.8.0011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!